Pygeum or Saw Palmetto: Which One to Try First, and Why

If saw palmetto has done nothing for you in three months, the useful next move is not a higher dose of it — it is a different mechanism. Pygeum has a Cochrane review behind it, works by a different route, and is dosed low enough that real products actually reach the studied amount. For night-time trips and flow, it is arguably the better first try.

What the research found

Pygeum has been assessed in a Cochrane systematic review — the most conservative kind of evidence summary there is. Pooling the randomised trials available, the review reported that men taking pygeum were about twice as likely to report improvement in overall symptoms, with reductions in nocturia and improvements in peak urine flow.

The reviewers were careful about it: the trials were small, mostly older, and methodologically inconsistent by modern standards. Their conclusion was that the evidence was promising but needed better studies — which, two decades later, still haven’t been funded. No patent, no funder; the familiar story.

Still, “a Cochrane review reported roughly twice the rate of symptom improvement” is a stronger sentence than almost anything else on this shelf can honestly claim.

The dose, and the good news about it

Trials generally used 100 to 200 mg daily of a standardised bark extract. That’s a low enough number that formulas can actually reach it — unlike saw palmetto’s 320 mg, which most blends miss by a factor of three or more.

The one formula we track that publishes its pygeum number carries 200 mg, which is at the top of the studied range. That’s a rare thing in this category and worth noticing when you see it.

How it’s thought to work

Mostly anti-inflammatory, with effects on the growth factors involved in prostate tissue proliferation. It also appears to improve bladder contractility, which would explain the flow findings better than a hormonal story would. Unlike saw palmetto, nobody claims pygeum is a 5-alpha-reductase story.

The part nobody mentions

Prunus africana is listed under CITES, the international convention on trade in endangered species. Bark harvesting killed a great many trees before the controls came in, and sustainable harvesting — taking bark in strips that let the tree recover — is now the standard but not universal practice.

If you’re going to take it for years, a supplier that says something about sourcing is worth preferring over one that doesn’t. This has nothing to do with whether it works and everything to do with whether it will still exist.

Who it suits

Someone whose main complaints are night-time trips and flow rather than discomfort, who wants the option with the most conservative evidence behind it, and who’d rather take something at a dose formulas can actually deliver.

Who should leave it alone

The safety record is good and the reported side effects are mild and gastrointestinal. Standard caution for anyone on prescription medication or with a condition under management — which, for a man taking an interest in his prostate, is a conversation worth having anyway.

The short version

Better evidence than its profile suggests, a dose that real products reach, and a conservation footnote. If saw palmetto hasn’t done anything for you in three months, pygeum is the next sensible thing to look at rather than a higher dose of the first one.